Ubs Group Ag Prelude Therapeutics Inc Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Ubs Group Ag holds 7,016 shares of PRLD stock, worth $9,401. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,016

Previous 10,934 35.83%

Holding current value

$9,401

Previous $41,000 65.85%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.07 - $6.37 $8,110 - $24,957	-3,918 Reduced 35.83%	7,016 $14,000
Q2 2024 Aug 13, 2024	SELL	$3.32 - $5.63 $15,673 - $26,579	-4,721 Reduced 30.16%	10,934 $41,000
Q1 2024 May 13, 2024	SELL	$2.68 - $4.84 $11,304 - $20,415	-4,218 Reduced 21.22%	15,655 $74,000
Q4 2023 Feb 09, 2024	BUY	$1.69 - $4.37 $21,065 - $54,472	12,465 Added 168.26%	19,873 $84,000
Q3 2023 Nov 09, 2023	BUY	$2.74 - $4.79 $1,413 - $2,471	516 Added 7.49%	7,408 $22,000
Q2 2023 Aug 11, 2023	BUY	$4.45 - $8.12 $26,308 - $48,005	5,912 Added 603.27%	6,892 $31,000
Q1 2023 May 12, 2023	SELL	$4.58 - $7.34 $261 - $418	-57 Reduced 5.5%	980 $5,000
Q4 2022 Feb 08, 2023	BUY	$4.61 - $8.5 $4,467 - $8,236	969 Added 1425.0%	1,037 $6,000
Q3 2022 Nov 10, 2022	SELL	$5.0 - $8.82 $13,190 - $23,267	-2,638 Reduced 97.49%	68 $0
Q2 2022 Aug 10, 2022	BUY	$4.0 - $7.55 $10,092 - $19,048	2,523 Added 1378.69%	2,706 $14,000
Q1 2022 May 16, 2022	SELL	$6.9 - $13.22 $12,109 - $23,201	-1,755 Reduced 90.56%	183 $1,000
Q4 2021 Feb 14, 2022	SELL	$11.89 - $31.74 $416,899 - $1.11 Million	-35,063 Reduced 94.76%	1,938 $23,000
Q3 2021 Nov 15, 2021	BUY	$25.78 - $38.65 $758,782 - $1.14 Million	29,433 Added 388.91%	37,001 $1.16 Million
Q2 2021 Aug 13, 2021	SELL	$28.63 - $44.3 $422,807 - $654,222	-14,768 Reduced 66.12%	7,568 $216,000
Q1 2021 May 12, 2021	BUY	$39.27 - $91.68 $775,778 - $1.81 Million	19,755 Added 765.4%	22,336 $968,000
Q4 2020 Feb 11, 2021	BUY	$28.81 - $88.94 $33,361 - $102,992	1,158 Added 81.38%	2,581 $185,000
Q3 2020 Nov 12, 2020	BUY	$26.2 - $30.13 $37,282 - $42,874	1,423 New	1,423 $43,000

Others Institutions Holding PRLD

# of Institutions

Shares Held

35.7M

Call Options Held

500

Put Options Held

300

View Full List

About Prelude Therapeutics Inc

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $48.7M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

More about PRLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account